• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Natera Reports First Quarter 2025 Financial Results

    5/8/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025.

    Recent Strategic and Financial Highlights

    • Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period.
    • Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024.
    • Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of 16.2%.
    • Performed approximately 167,700 oncology tests in the first quarter of 2025, compared to approximately 114,800 in the first quarter of 2024, an increase of 46.1%.
    • Achieved positive cash flow of approximately $23.2 million1 in the first quarter of 2025.

    "We delivered another strong quarter, with volume growth across the business, including a record growth quarter for Signatera," said Steve Chapman, chief executive officer of Natera. "Our progress reflects the strength of our technology and the breadth and quality of the clinical data. With multiple high-impact datasets reading out and trials underway, we believe we're in a strong position to help millions of patients in the future."

    First Quarter Ended March 31, 2025 Financial Results

    Total revenues were $501.8 million in the first quarter of 2025 compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. The increase in total revenues was driven primarily by a 37.1% increase in product revenues, which were $500.0 million in the first quarter of 2025 compared to $364.7 million in the first quarter of 2024. The increase in product revenues was primarily driven by an increase in volume and average selling price improvements, as well as cash receipts that were collected during the quarter in excess of initial revenue estimates for tests delivered in prior quarters.

    Natera processed approximately 855,100 tests in the first quarter of 2025, including approximately 840,800 tests accessioned in its laboratory, compared to approximately 735,800 tests processed, including approximately 718,700 tests accessioned in its laboratory, in the first quarter of 2024, an increase of 16.2% from the prior period.

    In the first quarter of 2025, Natera recognized revenue on approximately 804,800 tests for which results were reported to customers in the period (tests reported), including approximately 791,400 tests reported from its laboratory, compared to approximately 679,400 tests reported, including approximately 663,500 tests reported from its laboratory, in the first quarter of 2024, an increase of 18.5% from the prior period.

    Gross profit2 for the three months ended March 31, 2025 and 2024 was $316.8 million and $208.6 million, respectively, representing a gross margin of 63.1% and 56.7%, respectively. Natera had higher gross margin in the first quarter of 2025 primarily as a result of higher revenues, continued progress in reducing cost of revenues associated with tests processed, as well as incremental cash receipts during the quarter in excess of initial revenue estimates for tests delivered in the prior period. Total operating expenses, representing research and development expenses and selling, general and administrative expenses, for the first quarter of 2025 were $395.9 million, compared to $282.9 million in the same period of the prior year, an increase of 39.9%. The increase was primarily driven by headcount growth to support new product offerings as well as increases in consulting and legal expenses.

    Loss from operations for the first quarter of 2025 was $79.2 million compared to $74.3 million for the same period of the prior year.

    Natera reported a net loss for the first quarter of 2025 of $66.9 million, or ($0.50) per diluted share, compared to a net loss of $67.6 million, or ($0.56) per diluted share, for the same period in 2024. Weighted average shares outstanding were approximately 134.8 million in the first quarter of 2025 compared to 120.8 million in the first quarter of the prior year.

    At March 31, 2025, Natera held approximately $991.6 million in cash, cash equivalents, short-term investments and restricted cash, compared to $968.3 million as of December 31, 2024. As of March 31, 2025, Natera had a total outstanding debt balance of $80.3 million including accrued interest under its line of credit with UBS at a variable interest rate of 30-day SOFR plus 50 bps.

    Financial Outlook

    Natera anticipates 2025 total revenue of $1.94 billion to $2.02 billion; 2025 gross margin to be approximately 60% to 64% of revenues; selling, general and administrative costs to be approximately $0.975 billion to $1.05 billion; research and development costs to be $550 million to $590 million; and net cash inflow to be positive3.

    Unit

     

    Q1 2025

     

    Q1 2024

     

    Definition

    Tests processed

     

    855,100

     

    735,800

     

    Tests accessioned in our laboratory plus units processed outside of our laboratory

    Tests accessioned

     

    840,800

     

    718,700

     

    Test accessioned in our laboratory

    Tests reported

     

    804,800

     

    679,400

     

    Total tests reported

    Tests reported in our laboratory

     

    791,400

     

    663,500

     

    Total tests reported in our laboratory less units reported outside of our laboratory

    About Natera

    Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

    Conference Call Information

    Event:

    Natera's First Quarter 2025 Financial Results Conference Call

    Date:

    Thursday, May 8, 2025

    Time:

    1:30 p.m. PT (4:30 p.m. ET)

    Live Dial-In:

    1-888-596-4144 (Domestic)

    1-646-968-2525 (International)

    Conference ID:

    7684785

    Webcast Link:

    https://events.q4inc.com/attendee/454317205

    Forward-Looking Statements

    This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts, including statements regarding its market opportunity, anticipated products and launch schedules, reimbursement coverage and product costs, commercial and strategic partnerships and acquisitions, user experience, clinical trials and studies, and its strategies, goals and general business and market conditions, are forward-looking statements. Any forward-looking statements contained in this press release are based upon Natera's current plans, estimates, and expectations, as of the date of this release, and are not a representation that such plans, estimates, or expectations will be achieved.

    These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including: we face numerous uncertainties and challenges in achieving our financial projections and goals; we may be unable to further increase the use and adoption of our products through our direct sales efforts or through our laboratory partners; we have incurred net losses since our inception and we anticipate that we will continue to incur net losses for the foreseeable future; our quarterly results may fluctuate from period to period; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we may be unable to compete successfully with existing or future products or services offered by our competitors; we may engage in acquisitions, dispositions or other strategic transactions that may not achieve our anticipated benefits and could otherwise disrupt our business, cause dilution to our stockholders or reduce our financial resources; our products may not perform as expected; the results of our clinical studies may not support the use and reimbursement of our tests, particularly for microdeletions screening, and may not be able to be replicated in later studies required for regulatory approvals or clearances; if either of our primary CLIA-certified laboratories becomes inoperable, we will be unable to perform our tests and our business will be harmed; we rely on a limited number of suppliers or, in some cases, single suppliers, for some of our laboratory instruments and materials and may not be able to find replacements or immediately transition to alternative suppliers; if we are unable to successfully scale our operations, our business could suffer; the marketing, sale, and use of Panorama and our other products could result in substantial damages arising from product liability or professional liability claims that exceed our resources; we may be unable to expand, obtain or maintain third-party payer coverage and reimbursement for our tests, and we may be required to refund reimbursements already received; third-party payers may withdraw coverage or provide lower levels of reimbursement due to changing policies, billing complexities or other factors; we could incur substantial costs and delays complying with governmental regulations, including recently enacted FDA regulations regarding LDTs; litigation and other regulatory or governmental proceedings, related to our intellectual property or the commercialization of our tests, are costly, time- consuming, could result in our obligation to pay material judgments or incur material settlement costs, and could limit our ability to commercialize our tests; and any inability to effectively protect our proprietary technology could harm our competitive position or our brand..

    We discuss these and other risks and uncertainties in greater detail in the sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our periodic reports on Forms 10-K and 10-Q and in other filings that we make with the SEC from time to time. These documents are available on our website at www.natera.com under the Investor Relations section and on the SEC's website at www.sec.gov.

    We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, you should not place undue reliance on our forward-looking statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in our expectations.

    References

    1. Positive cash flow for the quarter ended March 31, 2025, is derived from the GAAP Statement of Cash Flows as follows: net cash provided by operating activities of $44.5 million, net cash provided by financing activities of $0.5 million, offset by net cash used in investing activities for purchases of property and equipment of $21.8 million.
    2. Gross profit is calculated as GAAP total revenues less GAAP cost of revenues. Gross margin is calculated as gross profit divided by GAAP total revenues.
    3. Cash (outflow) inflow is calculated as the sum of GAAP net cash provided by (used in) operating activities, GAAP net cash provided by (used in) financing activities, and GAAP net cash provided by (used in) investing activities for purchases of property and equipment, investment in related party, and acquisition of intangible assets.

    Natera, Inc.

    Consolidated Balance Sheets

    (Unaudited)

    (in thousands, except shares)

     

     

     

     

     

     

     

     

     

     

     

    March 31,

     

     

    December 31,

     

     

     

     

    2025

     

     

    2024 (1)

     

    Assets

     

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

     

    Cash, cash equivalents and restricted cash

     

    $

    973,768

     

     

    $

    945,587

     

     

    Short-term investments

     

     

    17,832

     

     

     

    22,689

     

     

    Accounts receivable, net of allowance of $7,434 and $7,259 at March 31, 2025 and December 31, 2024, respectively

     

     

    318,233

     

     

     

    314,165

     

     

    Inventory

     

     

    50,367

     

     

     

    44,744

     

     

    Prepaid expenses and other current assets, net

     

     

    56,185

     

     

     

    48,635

     

     

    Total current assets

     

     

    1,416,385

     

     

     

    1,375,820

     

     

    Property and equipment, net

     

     

    180,453

     

     

     

    162,046

     

     

    Operating lease right-of-use assets

     

     

    94,631

     

     

     

    86,149

     

     

    Other assets

     

     

    40,897

     

     

     

    36,720

     

     

    Total assets

     

    $

    1,732,366

     

     

    $

    1,660,735

     

     

    Liabilities and Stockholders' Equity

     

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

     

    Accounts payable

     

    $

    39,240

     

     

    $

    34,922

     

     

    Accrued compensation

     

     

    47,086

     

     

     

    62,114

     

     

    Other accrued liabilities

     

     

    178,449

     

     

     

    146,893

     

     

    Deferred revenue, current portion

     

     

    20,557

     

     

     

    19,754

     

     

    Short-term debt financing

     

     

    80,345

     

     

     

    80,362

     

     

    Total current liabilities

     

     

    365,677

     

     

     

    344,045

     

     

    Deferred revenue, long-term portion and other liabilities

     

     

    23,958

     

     

     

    24,682

     

     

    Operating lease liabilities, long-term portion

     

     

    103,056

     

     

     

    96,588

     

     

    Total liabilities

     

     

    492,691

     

     

     

    465,315

     

     

     

     

     

     

     

     

     

     

    Commitments and contingencies

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Stockholders' equity:

     

     

     

     

     

     

     

    Common stock (2)

     

     

    14

     

     

     

    12

     

     

    Additional paid-in capital

     

     

    3,874,656

     

     

     

    3,763,614

     

     

    Accumulated deficit

     

     

    (2,634,798

    )

     

     

    (2,567,862

    )

     

    Accumulated other comprehensive loss

     

     

    (197

    )

     

     

    (344

    )

     

    Total stockholders' equity

     

     

    1,239,675

     

     

     

    1,195,420

     

     

    Total liabilities and stockholders' equity

     

    $

    1,732,366

     

     

    $

    1,660,735

     

     

    (1)

    The consolidated balance sheet at December 31, 2024 has been derived from the audited consolidated financial statements at that date included in the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

    (2)

    As of March 31, 2025 and December 31, 2024, there were approximately 135,932,000 and 132,646,000 shares of common stock issued and outstanding, respectively.

    Natera, Inc.

    Consolidated Statements of Operations and Comprehensive Loss

    (Unaudited)

    (in thousands, except per share data)

     

    Three months ended

     

     

    March 31,

     

     

    2025

     

    2024

     

     

     

     

     

     

    Revenues

     

     

     

     

     

     

    Product revenues

     

    $

    500,036

     

     

    $

    364,672

     

    Licensing and other revenues

     

     

    1,794

     

     

     

    3,069

     

    Total revenues

     

     

    501,830

     

     

     

    367,741

     

    Cost and expenses

     

     

     

     

     

     

    Cost of product revenues

     

     

    184,613

     

     

     

    158,833

     

    Cost of licensing and other revenues

     

     

    452

     

     

     

    307

     

    Research and development

     

     

    129,078

     

     

     

    88,637

     

    Selling, general and administrative

     

     

    266,864

     

     

     

    194,278

     

    Total cost and expenses

     

     

    581,007

     

     

     

    442,055

     

    Loss from operations

     

     

    (79,177

    )

     

     

    (74,314

    )

    Interest expense

     

     

    (1,005

    )

     

     

    (3,124

    )

    Interest and other income, net

     

     

    13,419

     

     

     

    10,267

     

    Loss before income taxes

     

     

    (66,763

    )

     

     

    (67,171

    )

    Income tax expense

     

     

    (173

    )

     

     

    (428

    )

    Net loss

     

    $

    (66,936

    )

     

    $

    (67,599

    )

    Unrealized gain on available-for-sale securities, net of tax

     

     

    147

     

     

     

    893

     

    Comprehensive loss

     

    $

    (66,789

    )

     

    $

    (66,706

    )

     

     

     

     

     

     

     

    Net loss per share:

     

     

     

     

     

     

    Basic and diluted

     

    $

    (0.50

    )

     

    $

    (0.56

    )

    Weighted-average number of shares used in computing basic and diluted net loss per share:

     

     

     

     

     

     

    Basic and diluted

     

     

    134,750

     

     

     

    120,814

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250508576112/en/

    Investor Relations

    Mike Brophy, CFO, Natera, Inc., [email protected]

    Media

    Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., [email protected]

    Get the next $NTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    2/20/2024$68.00 → $85.00Strong Buy → Outperform
    Raymond James
    12/29/2023$75.00 → $85.00Buy
    BTIG Research
    12/14/2023$70.00Buy
    Guggenheim
    12/13/2023$70.00Outperform
    Wolfe Research
    More analyst ratings

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

      Demonstrates Signatera's ability to predict long-term outcomes in early-stage, high-risk breast cancers Several datasets will be presented, highlighting Natera's leadership in breast cancer MRD Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712 patients with early-stage, high-ris

      5/8/25 10:30:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

      Study published in American Journal of Transplantation highlights strong sensitivity and specificity, along with a >37% reduction in false positives when using Prospera Heart with DQS Adds to the growing body of evidence supporting DQS for dd-cfDNA analysis in solid organ transplant Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total c

      5/7/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marcus Gail Boxer exercised 4,000 shares at a strike of $24.42 and sold $606,433 worth of shares (4,000 units at $151.61) (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      5/2/25 9:35:05 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • CEO AND PRESIDENT Chapman Steven Leonard sold $1,047,702 worth of shares (6,980 units at $150.10), decreasing direct ownership by 4% to 185,182 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      5/2/25 9:35:09 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • PRESIDENT, CLINICALDIAGNOSTICS Moshkevich Solomon sold $450,353 worth of shares (3,000 units at $150.12), decreasing direct ownership by 2% to 136,205 units (SEC Form 4)

      4 - Natera, Inc. (0001604821) (Issuer)

      5/2/25 9:35:07 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Financials

    Live finance-specific insights

    See more
    • Natera Reports First Quarter 2025 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the first quarter ended March 31, 2025. Recent Strategic and Financial Highlights Generated total revenues of $501.8 million in the first quarter of 2025, compared to $367.7 million in the first quarter of 2024, an increase of 36.5%. Product revenues grew 37.1% over the same period. Generated a gross margin of 63.1% in the first quarter of 2025, compared to a gross margin of 56.7% in the first quarter of 2024. Processed approximately 855,100 tests in the first quarter of 2025, compared to approximately 735,800 tests in the first quarter of 2024, an increase of

      5/8/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera to Report its First Quarter Results on May 8, 2025

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2025, after the market closes on May 8, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's First Quarter 2025 Financial Results Date: May 8, 2025 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In: 1-888-596-4144 (Domestic) 1-646-968-2525 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/454317205 A webcast replay will be available at

      5/1/25 7:00:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Reports Fourth Quarter and Full Year 2024 Financial Results

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Recent Financial Highlights Generated total revenues of $476.1 million in the fourth quarter of 2024, compared to $311.1 million in the fourth quarter of 2023, an increase of 53.0%. Product revenues grew 53.9% over the same period. Generated a gross margin of 62.9% in the fourth quarter of 2024, compared to a gross margin of 51.4% in the fourth quarter of 2023. Generated total revenues of $1,696.9 million in the full year of 2024, compared to $1,082.6 million in the full year 2023, an increase of 56.7%

      2/27/25 4:05:00 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RBC Capital Mkts initiated coverage on Natera with a new price target

      RBC Capital Mkts initiated coverage of Natera with a rating of Outperform and set a new price target of $251.00

      3/13/25 8:17:14 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Natera with a new price target

      Barclays initiated coverage of Natera with a rating of Overweight and set a new price target of $200.00

      1/23/25 7:51:22 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Jefferies resumed coverage on Natera with a new price target

      Jefferies resumed coverage of Natera with a rating of Buy and set a new price target of $142.00

      6/3/24 8:16:05 AM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Natera Inc.

      10-Q - Natera, Inc. (0001604821) (Filer)

      5/8/25 7:35:38 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Natera, Inc. (0001604821) (Filer)

      5/8/25 4:15:22 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Natera Inc.

      DEFA14A - Natera, Inc. (0001604821) (Filer)

      4/24/25 5:11:05 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Natera Inc.

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      11/14/24 4:02:50 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      6/7/24 12:07:25 PM ET
      $NTRA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Natera Inc. (Amendment)

      SC 13G/A - Natera, Inc. (0001604821) (Subject)

      2/14/24 4:06:56 PM ET
      $NTRA
      Medical Specialities
      Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

      Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

      6/5/23 11:06:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

      Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

      2/23/23 8:05:00 AM ET
      $NTRA
      Medical Specialities
      Health Care
    • Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology

      AUSTIN, Texas, May 24, 2022  /PRNewswire/ -- Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu, M.D., as its new chief medical officer (CMO) of oncology. In this role, Dr. Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera™ and incorporate it into standard medical practice across tumor types. "I am very pleased to welcome Dr. Liu to Natera," said Solomon Moshkevich, general manager of oncology at Natera. "As a highly reg

      5/24/22 8:03:00 AM ET
      $NTRA
      Medical Specialities
      Health Care